Treatment of osteoporosis is associated with adverse cardiovascular events

Source/Disclosure Disclosure: Bovijn reported that he is a consultant to the Bill and Melinda Gates Foundation Strategic Investment Fund. See Research for relevant financial information for all other authors. Add topics to email alerts Get an email when a new article is posted Enter your email address to receive an email when a new article is posted .. "data-action " subscribe "> Subscribe The request could not be processed. Please try again later. If you continue to have this issue, please contact us customerservice@slackinc.com.. Return to Healio Homogeneity, a monoclonal antibody that inhibits sclerostin used to treat osteoporosis, may increase the risk of cardiovascular events in patients Science Translational Medicine.. “Our findings support the addition of cardiovascular risk alerts by the US FDA and EMA.Labeling and showing that other therapies that block sclerostin are likely to have similar cardiovascular effects.” Jonas Bovijn, MBChB, MSc, DLSHTM, A member of the Big Data Institute at the Li Ka Shing Center for Health Information and Discovery at Oxford University, written by a colleague. Homogeneity, a monoclonal antibody that inhibits sclerostin used to treat osteoporosis, may increase the risk of cardiovascular events in patients Science Translational Medicine.. Source: Adobe Stock. Bovijn and colleagues conducted a meta-analysis of published and unpublished data on cardiovascular outcomes in a study with romosozumab to investigate whether genetic mutations that mimic sclerostin treatment inhibition were associated with an increased risk of CVD. .. They found that taking 210 mg of lomosozumab per month was associated with an increased risk of cardiac ischemic events, based on the results of two phase 3 randomized controlled trials involving 25 events from 4,298 participants. (OR 2.98; 95% CI, 1.18-7.55). When researchers scale SOST A dose of genetic variant equivalent to romosozumab was Reduces risk of fracture Onset of osteoporosis. However, they also found that these variants increased the risk of myocardial infarction and/or coronary revascularization by 18% (69,649 cases; OR 1.18; 95% CI, 1.06-1.32) and 12% of major adverse cardiovascular events. We also confirmed that it was associated with increased risk (119,032 cases; OR 1.12; 95% CI, 1.03-1.21). When the researchers expanded the definition of coronary heart disease to include self-reported angina and chronic stable ischemic heart disease, these variants increased the risk of heart disease by 10% (106,329 cases; OR 1.1; 95% CI, 1 -1.2). "Our results ensure that we rigorously evaluate the effects of romosozumab (and other sclerostin inhibitors in clinical development) on cardiovascular disease and cardiometabolic risk factors," Bovijn and colleagues said. .. "This adds valuable information to whether pharmacological inhibition of sclerostin should be pursued as a therapeutic strategy for fracture prevention." Add topics to email alerts Get an email when a new article is posted Enter your email address to receive an email when a new article is posted .. "data-action " subscribe "> Subscribe The request could not be processed. Please try again later. If you continue to have this issue, please contact us customerservice@slackinc.com.. Return to Healio Pictures Credit

ExBulletin

Treatment of osteoporosis is associated with adverse cardiovascular events

Health

Treatment of osteoporosis is associated with adverse cardiovascular events

Related

Recent Posts

Add ExBulletin to your Home screen!